Effect of Tocopheryl Polyethylene Glycol Succinate on the Percutaneous Penetration of Minoxidil from Water/Ethanol/Polyethylene Glycol 400 Solutions

ABSTRACT We described to achieve the local retention of minoxidil which has penetrated the skin with minimization of its absorption into the general circulation and elimination of local irritation induced by propylene glycol. The effect of tocopheryl polyethylene glycol succinate (TPGS) on the penetration flux of minoxidil and its retention in the skin from topical minoxidil formulations consisting of water, alcohol, and polyethylene glycol 400 was characterized by an experimental design of ten solvent formulations in this study. Results show that the addition of TPGS was only able to improve the solubility of minoxidil in those solvent systems containing higher proportions of water and PEG 400, and the extent of improvement was also more profound with the addition of TPGS at concentrations higher than 5%. For those solvent systems containing a higher fraction of alcohol, an insignificant change in minoxidil solubility with increasing added amounts of TPGS was noted even with the tendency to decrease the solubility of minoxidil with higher amounts of TPGS. Increasing the amount of TPGS added gradually increased the flux and the corrected flux from solvent formulations with a lower solubility parameter, but decreased those from solvent systems with a higher solubility parameter. With the addition of TPGS, solvent formulation F6 (alcohol:PEG 400 of 50:50) was demonstrated to be the optimal choice by having an improved local effect and a reduced systemic effect compared to the reference of 2% Regaine®. Tocopheryl polyethylene glycol succinate (TPGS) was mainly retained locally in the stratum corneum, and the amount was proportional to the increase in the amount of TPGS added to these ten solvent formulations.

[1]  Lawrence X. Yu,et al.  Vitamin E-TPGS Increases Absorption Flux of an HIV Protease Inhibitor by Enhancing Its Solubility and Permeability1 , 1999, Pharmaceutical Research.

[2]  Ling-chun Chen,et al.  Influence of micelle solubilization by tocopheryl polyethylene glycol succinate (TPGS) on solubility enhancement and percutaneous penetration of estradiol. , 2003, Journal of controlled release : official journal of the Controlled Release Society.

[3]  D. West,et al.  Alternative formulation for patients with contact reactions to topical 2% and 5% minoxidil vehicle ingredients. , 2000, Contact dermatitis.

[4]  N. Weiner,et al.  Penetration of minoxidil from ethanol/propylene glycol solutions: effect of application volume and occlusion. , 1995, Journal of pharmaceutical sciences.

[5]  N. Weiner,et al.  Relative influence of ethanol and propylene glycol cosolvents on deposition of minoxidil into the skin. , 1994, Journal of pharmaceutical sciences.

[6]  F. Suchy,et al.  Multicenter trial of d-alpha-tocopheryl polyethylene glycol 1000 succinate for treatment of vitamin E deficiency in children with chronic cholestasis. , 1993, Gastroenterology.

[7]  N. Weiner,et al.  Drug and vehicle deposition from topical applications: use of in vitro mass balance technique with minoxidil solutions. , 1992, Journal of pharmaceutical sciences.

[8]  S. E. Whitmore The importance of proper vehicle selection in the detection of minoxidil sensitivity. , 1992, Archives of dermatology.

[9]  M. Traber,et al.  Uptake of intact TPGS (d-alpha-tocopheryl polyethylene glycol 1000 succinate) a water-miscible form of vitamin E by human cells in vitro. , 1988, The American journal of clinical nutrition.

[10]  V. Fiedler‐Weiss Topical minoxidil solution (1% and 5%) in the treatment of alopecia areata. , 1987, Journal of the American Academy of Dermatology.

[11]  K. C. James,et al.  Solubility and Related Properties , 1986 .

[12]  S. Veronesi,et al.  Contact dermatitis to Minoxidil , 1985, Contact dermatitis.

[13]  T. Franz Percutaneous absorption of minoxidil in man. , 1985, Archives of dermatology.

[14]  Vilches Ar,et al.  Case 32-1980: minimal-change disease with mesangial IgM deposits. , 1980 .

[15]  Zappacosta Ar,et al.  Reversal of baldness in patient receiving minoxidil for hypertension. , 1980 .

[16]  J. Burton,et al.  Hypertrichosis due to minoxidil , 1979, The British journal of dermatology.

[17]  G. Dunea,et al.  Severe hypertension. Treatment with minoxidil. , 1975, JAMA.